DOD Neurofibromatosis Exploration - Hypothesis Development Award

The summary for the DOD Neurofibromatosis Exploration - Hypothesis Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Neurofibromatosis Exploration - Hypothesis Development Award: The Exploration - Hypothesis Development Award (EHDA) mechanism is being offered for the first time in FY08. The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, untested, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or it should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to a lack of available information. The presentation of preliminary data is encouraged, but not required. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded. The FY08 NFRP encourages proposals that specifically address critical needs of the NF community in the following areas: . Translational research such as the development or preclinical testing of therapeutic agents for the treatment of neurofibromatosis; . Complications of neurofibromatosis with high mortality such as childhood neoplasms, malignant peripheral nerve sheath tumors, and cerebrovascular abnormalities; . Complications of neurofibromatosis with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects and pain; . Refinement and standardization of imaging techniques and biomarkers for use in future clinical trials.